(R)-N-(tert-butoxycarbonyl)-2-methylindoline | 197460-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (R)-N-(tert-butoxycarbonyl)-2-methylindoline
• 英文别名: tert-butyl (2R)-2-methyl-2,3-dihydroindole-1-carboxylate
• CAS: 197460-39-2
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: HRXYFPYEGYHYGJ-SNVBAGLBSA-N

物化性质

• 沸点：
  313.8±12.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-N-(tert-butoxycarbonyl)-2-methylindoline 在 TEA 、 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 氯仿 、 乙腈 为溶剂， 反应 35.0h， 生成 2-[4-(4-Chloro-benzyl)-piperazin-1-yl]-1-((R)-2-methyl-2,3-dihydro-indol-1-yl)-ethanone
  参考文献：
  名称：

  Indoline and piperazine containing derivatives as a novel class of mixed D2/D4 receptor antagonists. Part 2: Asymmetric synthesis and biological evaluation

  摘要：

  A series of chiral benzylpiperazinyl-1-(2,3-dihydro-indol-1-yl)ethanone derivatives were prepared and examined for their affinity at dopamine D-2 and D-4 receptors. Three compounds having D-2/D-4 affinity ratios approximating that found for the atypical neuroleptic clozapine were further evaluated in behavioral tests of antipsychotic efficacy and motor side effects. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00656-x
• 作为产物：
  描述：

  tert-butyl 2-methyl-1H-indole-1-carboxylate 在 氢气 、 C₃₉H₃₆IrNOP⁽¹⁺⁾*C₃₂H₁₂BF₂₄^(1-) 作用下， 以 二氯甲烷 为溶剂， 25.0 ℃ 、8.11 MPa 条件下， 反应 24.0h， 以99%的产率得到(R)-N-(tert-butoxycarbonyl)-2-methylindoline
  参考文献：
  名称：

  铱和苯并呋喃衍生物的铱催化对映选择性加氢。

  摘要：

  通过使用Ir / SpinPHOX（SpinPHOX = spiro [4,4] -1,6-壬二烯基膦，已经实现了对N，O和S的各种芳族苯并杂环或非芳族不饱和杂环的对映选择性氢化） -恶唑啉）络合物作为催化剂，可提供一系列相应的手性苯并杂环化合物（30个实例），具有出色的对映选择性（大多数情况下> 99％  ee），周转数高达500。

  DOI：

  10.1002/chem.202002532

文献信息

• [EN] FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS<br/>[FR] UTILISATION DE DÉRIVÉS THIAZOLOPYRIMIDINE FUSIONNÉS COMME INHIBITEURS DE MNSK
  申请人：MEDICAL RES COUNCIL TECH

  公开号：WO2017085484A1

  公开（公告）日：2017-05-26

  The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.

  本发明涉及公式I和H的化合物，或其药用盐或酯。该发明的进一步方面涉及药物组合物以及所述化合物在治疗未受控制的细胞生长、增殖和/或存活、不当的细胞免疫反应、不当的细胞炎症反应或神经退行性疾病，更好地说是tau病变疾病，甚至更好地说是阿尔茨海默病的治疗用途。
• Catalytic asymmetric hydrogenation of indoles using a rhodium complex with a chiral bisphosphine ligand PhTRAP
  作者：Ryoichi Kuwano、Manabu Kashiwabara、Koji Sato、Takashi Ito、Kohei Kaneda、Yoshihiko Ito

  DOI：10.1016/j.tetasy.2006.01.016

  日期：2006.2

  Highly enantioselective hydrogenation of N-protected indoles was successfully developed by use of the rhodium catalyst generated in situ from [Rh(nbd)2]SbF6 and the chiral bisphosphine PhTRAP, which can form a trans-chelate complex with a transition metal atom. The PhTRAP–rhodium catalyst required a base (e.g., Cs2CO3) for the achievement of high enantioselectivity. Various 2-substituted N-acetylindoles

  通过使用由[Rh（nbd）2 ] SbF 6原位生成的铑催化剂和手性双膦PhTRAP，可以成功地开发出N-保护的吲哚的高度对映选择性氢化反应，可以与过渡金属原子形成反式-螯合物。PhTRAP-铑催化剂需要碱（例如Cs 2 CO 3）才能实现高对映选择性。将各种2-取代的N-乙酰吲哚转化为具有高达95％ee的相应的手性二氢吲哚。3-取代的N - tosylindoles的氢化产生二氢吲哚，其在3-位具有立体异构中心，具有高的对映异构体过量（至多98％ee）。
• Ruthenium-Catalyzed Asymmetric Hydrogenation of <i>N</i>-Boc-Indoles
  作者：Ryoichi Kuwano、Manabu Kashiwabara

  DOI：10.1021/ol061039x

  日期：2006.6.1

  enantioselective hydrogenation of various N-Boc-indoles proceeded successfully in the presence of the ruthenium complex generated from an appropriate ruthenium precursor and a trans-chelate chiral bisphosphine PhTRAP. Various 2- or 3-substituted indoles were converted into chiral indolines with high enantiomeric excesses (up to 95% ee). The PhTRAP-ruthenium catalyst was able to promote the hydrogenation of 2,3-dimethylindoles

  在适当的钌前体和反式螯合手性双膦PhTRAP生成的钌络合物存在下，成功进行了各种N-Boc-吲哚的高度对映选择性氢化。各种2-或3-取代的吲哚被转化为具有高对映体过量（至多95％ee）的手性二氢吲哚。PhTRAP-钌催化剂能够促进2，3-二甲基吲哚的氢化，得到具有72％ee的顺式2,3-二甲基二氢吲哚。
• [EN] MORPHOLINO COMPOUNDS, USES AND METHODS<br/>[FR] COMPOSÉS MORPHOLINO, UTILISATIONS ET PROCÉDÉS
  申请人：UNIV DUNDEE

  公开号：WO2012160392A1

  公开（公告）日：2012-11-29

  The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.

  该发明涉及根据式（I）的吗啡啉衍生物或其立体异构体或药用可接受的盐或溶剂化物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、m和n如规范中定义。这些化合物是G蛋白偶联受体的拮抗剂、逆向激动剂或激动剂，例如多巴胺D4和5HT1a。该发明还涉及包括这些化合物的药物组合物和涉及这些化合物和组合物的方法。该发明的化合物和组合物特别可用于治疗疾病和疾病，如神经和神经退行性疾病；或作为设计和选择更多治疗化合物的引导化合物。
• MORPHOLINO COMPOUNDS, USES AND METHODS
  申请人：University of Dundee

  公开号：US20140148452A1

  公开（公告）日：2014-05-29

  The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , m and n are as defined in the specification. The compounds are antagonists, reverse agonists or agonists of G-protein coupled receptors, such as dopamine D4 and 5HT1a. The inventions also relates to pharmaceutical compositions comprising the compounds and methods involving the compounds and compositions. The compounds and compositions of the invention may in particular be used in the treatment of diseases and disorders, such as neurological and neurodegenerative diseases; or as lead compounds for the design and selection of further therapeutic compounds.

  该发明涉及按照式(I)的吗啡啉衍生物或其立体异构体或药用可接受的盐或溶剂，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、m和n如规范中定义。这些化合物是G蛋白偶联受体的拮抗剂、反向激动剂或激动剂，例如多巴胺D4和5HT1a。该发明还涉及包括这些化合物的药物组合物和涉及这些化合物和组合物的方法。该发明的化合物和组合物特别可用于治疗疾病和障碍，如神经系统和神经退行性疾病；或作为设计和选择进一步治疗化合物的引导化合物。